Early data on Hansoh’s HS-20089 were enough to tempt GSK, but Seagen isn't far behind.

Astra manages to avoid the toxicities that scuppered Lilly’s PD-1 x TIM-3 contender, but still needs to dial up sabestomig’s efficacy.

But toxicity will be closely watched in future trials.

The numerical survival benefit versus Keytruda underperform’s Merck’s phase 3 study, but there’s a possible reason for that.

In paying $5.5bn for immediate rights to three Daiichi Sankyo assets Merck & Co has made its biggest bet on ADCs to date.

But late-breaking data raise questions about lack of a dose response.